Intestinal Stem Cell Marker ASCL2 is a Novel Prognostic Predictor in Esophageal Adenocarcinoma.

Cureus · 2022 · PMC8818334 · PMID 35154991

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The percentage of ASCL2 high is 33.3% in pathological Stage I/II, 45% in Stage III, and 77.8% in Stage IV but did not reach statistical significance due to the small number of Stage I/II cases in our study.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.